Analyst Stacy Ku from TD Cowen maintained a Buy rating on KalVista Pharmaceuticals and keeping the price target at $30.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Stacy Ku has given her Buy rating due to a combination of factors that highlight the promising outlook for KalVista Pharmaceuticals. The early launch metrics for Ekterly, their new oral treatment for acute HAE, have been impressive, with significant clinician activation and steady progress in access and reimbursement. This positive momentum is supported by key opinion leaders who anticipate strong patient demand due to Ekterly’s unique profile as an oral agent with efficacy comparable to subcutaneous options.
Additionally, the initial sales figures, although covering only a short period post-approval, suggest that the launch is progressing well. The substantial number of patient start forms and the willingness of payors to support chronic use further reinforce the optimistic outlook. The company’s strategic initiatives, such as a free bridge program and medical exemptions for reimbursement, are expected to facilitate patient adoption and drive sales growth. Overall, these factors contribute to the expectation of significant market penetration and revenue generation for Ekterly, justifying the Buy rating.